Laparoscopy firm SurgRx attracts former Novacept backer in fundraising
This article was originally published in Clinica
New Enterprise Associates, the long-established venture capital firm that backed Novacept through to its acquisition by Cytyc for $325m last year, has led a $21m investment round in SurgRx. Menlo Park, California-based SurgRx has developed an FDA-approved laparoscopic instrument, EnSeal, that operates via a radiofrequency controller and "Smart Electrode" sensor to cut and seal blood vessels and tissue while minimising thermal damage to adjacent tissue.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.